Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17ClN2O5 |
Molecular Weight | 388.802 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)C1=NOC(=C1C2=CC=C(OC)C=C2)C3=CC(Cl)=C(O)C=C3O
InChI
InChIKey=JXPCDMPJCKNLBY-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O5/c1-3-21-19(25)17-16(10-4-6-11(26-2)7-5-10)18(27-22-17)12-8-13(20)15(24)9-14(12)23/h4-9,23-24H,3H2,1-2H3,(H,21,25)
Molecular Formula | C19H17ClN2O5 |
Molecular Weight | 388.802 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17431102Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19244114 | https://www.ncbi.nlm.nih.gov/pubmed/24292262
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/19244114 | https://www.ncbi.nlm.nih.gov/pubmed/24292262
VER-50589 is an isoxazole compound that inhibits a heat shock protein Hsp90. Mean cellular antiproliferative GI(50) value for VER-50589 for a human cancer cell line panel were 78 nM/L, showing a 9-fold potency gain for the isoxazole. VER-50589 shows favorable pharmacokinetics and impairs tumor growth (colon cancer) in animal model. Glioblastoma cells do not acquire resistance to VER-50589 and resistance to other Hsp90 inhibitors does not produce cross-resistance to VER-50589.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102 |
21.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. | 2007 Apr |
|
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. | 2008 Jan 24 |
|
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. | 2017 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102
Nine daily doses of 100 mg/kg
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17431102
VER-50589 inhibited HUVEC proliferation with GI50 values of 19 nM/L, respectively. The nontumorigenic
human breast (MCF10a) and prostate (PNT2) epithelial cells exhibited higher GI50 values for VER-
50589 when compared with their respective mean GI50 (330 nM/l and 179.5 nM/l respectively) values against cancer cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:43:53 GMT 2023
by
admin
on
Sat Dec 16 15:43:53 GMT 2023
|
Record UNII |
H4E4ND635H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135446210
Created by
admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
|
PRIMARY | |||
|
747413-08-7
Created by
admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
|
PRIMARY | |||
|
H4E4ND635H
Created by
admin on Sat Dec 16 15:43:53 GMT 2023 , Edited by admin on Sat Dec 16 15:43:53 GMT 2023
|
PRIMARY |